TP53 status and impact on AML prognosis within the ELN 2022 risk classification

Shaun Fleming; Xavier Cheng-Hong Tsai; Rhiannon Morris; Hsin-An Hou; Andrew H Wei

doi:10.1182/blood.2023020855

TP53 status and impact on AML prognosis within the ELN 2022 risk classification

Blood. 2023 Dec 7;142(23):2029-2033. doi: 10.1182/blood.2023020855.

Authors

Shaun Fleming^{1

2}, Xavier Cheng-Hong Tsai³, Rhiannon Morris⁴, Hsin-An Hou³, Andrew H Wei^{4

5}

Affiliations

¹ Australian Centre for Blood Diseases, Monash University, Melbourne, Australia.
² Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia.
³ Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
⁴ Division of Blood Cells and Blood Cancer, Walter and Eliza Hall Institute of Medical Research and University of Melbourne, Melbourne, Australia.
⁵ Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Australia.

PMID: 37647854
DOI: 10.1182/blood.2023020855

Abstract

This study reports the following: (1) frequency of TP53 comutation within each component of the European LeukemiaNet 2022 acute myeloid leukemia risk classification, (2) relevance of TP53 mutated variant allelic fraction <10%, (3) prognostic impact of -7, -5/del(5q), -17/abn(17p), complex karyotype/monosomal karyotype, or myelodysplasia-related gene mutations with/without mutated TP53.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Abnormal Karyotype
Humans
Leukemia, Myeloid, Acute* / genetics
Mutation
Myelodysplastic Syndromes* / genetics
Prognosis
Tumor Suppressor Protein p53 / genetics

Substances

Tumor Suppressor Protein p53
TP53 protein, human